NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.25 Consensus PT from Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $33.25.

A number of analysts recently issued reports on the company. Scotiabank assumed coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 price objective on the stock. TD Cowen assumed coverage on NewAmsterdam Pharma in a report on Wednesday, May 15th. They set a “buy” rating on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, June 7th.

Read Our Latest Report on NAMS

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson purchased 5,000 shares of the stock in a transaction on Thursday, June 20th. The shares were purchased at an average price of $17.26 per share, with a total value of $86,300.00. Following the acquisition, the chief executive officer now directly owns 204,784 shares in the company, valued at approximately $3,534,571.84. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of the company. Wolverine Asset Management LLC increased its position in shares of NewAmsterdam Pharma by 197.2% during the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock valued at $97,000 after purchasing an additional 5,769 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its position in shares of NewAmsterdam Pharma by 12.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock valued at $598,000 after purchasing an additional 7,400 shares during the last quarter. Yarbrough Capital LLC bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $567,000. Opaleye Management Inc. increased its position in shares of NewAmsterdam Pharma by 18.8% during the 1st quarter. Opaleye Management Inc. now owns 315,388 shares of the company’s stock valued at $7,459,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of NewAmsterdam Pharma by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after purchasing an additional 51,726 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Trading Up 4.4 %

NAMS stock opened at $20.87 on Thursday. NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35. The stock has a fifty day moving average of $19.72 and a 200-day moving average of $19.78.

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.08). The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $2.95 million. Analysts anticipate that NewAmsterdam Pharma will post -2.52 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

(Get Free Report

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Further Reading

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.